Explore Xeris Biopharma's revenue growth, promising pipeline, & thriving products. Learn about their strong outlook & ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
Falling short of expectations, Novo Nordisk said its investigational fixed-dose combination of cagrilintide and semaglutide ...
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
One of the losers of today's trading session was Novo Nordisk A/S. Shares of the Pharmaceutical company plunged -9.8%, and some investors may be wondering if its price of $78.63 would make a good ...
How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...
Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...
Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra’s obesity drug. AI takes center stage at HIMSS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results